Using a closed-cell design, the CYPHER stent delivers sirolimus, a drug that selectively targets and interrupts proliferating cells early in the cell cycle, halting the development of neointimal hyperplasia while allowing natural healing and normal re-endothelialization. It is available in over-the-wire and rapid exchange delivery systems. It comes in 8, 13, 18, 28 and 30 mm lengths and has radio-opaque markers.
July 2, 2024 — Biotronik announced the availability of an expanded Maximum Allowed Diameters (MAD) range for the Orsiro ...
July 02, 2024 
October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...
October 31, 2023 
October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...
October 10, 2023 
July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...
July 13, 2023 
July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...
July 12, 2023 
May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...
May 25, 2023 
January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...
January 02, 2023 
December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...
December 23, 2022 
June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...
June 02, 2022 
February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...
February 16, 2022